AACR 2023 Highlights: CAR-T Therapies and Monoclonal Antibody Combinations in Cancer Research
The 2023 edition of the American Association for Cancer Research (AACR) annual meeting has concluded,...
Cancer
BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced that the...
Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has published the results of the Phase III...
CSPC Pharmaceutical Group Gets NMPA Approval for SYS6010 ADC Clinical Trial
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...
Legend Biotech’s Carvykti Data Boosts Stock Price by 19.64% on Positive Phase III Results
Shares of Legend Biotech (NASDAQ: LEGN) jumped an impressive 19.64% in a single day, attributed...
CARSgen Therapeutics’ CT041 Receives NMPA Approval for Post-Operative Pancreatic Cancer Therapy
China-based chimeric antigen receptor (CAR)-T cell specialist, CARSgen Therapeutics Holdings Ltd (HKG: 2171), has announced...
Zelgen Biopharmaceuticals’ ZG2001 Receives NMPA Approval for Clinical Trials
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
Beijing Aosaikang’s ASKG915 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...
InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for Recurrent/Refractory MZL Treatment
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving another indication approval from the...
Biosyngen Receives US FDA IND Approval for T-Cell Redirection Therapy for EBV-Positive Lymphoma
Biosyngen Pte Ltd, a cell and gene therapy (CGT) biotech with operations in Singapore and...
RemeGen Ltd Partners with Shandong Cancer Hospital for ADC Development and Integrated System
RemeGen Ltd (HKG: 9995) has announced a strategic partnership with Shandong Cancer Hospital to establish...
Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting
China-based Innovent Biologics (HKG: 1801) has published the results of a Phase I clinical study...
Adagene Inc. Presents Positive Interim Results for ADG126 at AACR Annual Meeting
China-based Adagene Inc. (NASDAQ: ADAG) has announced interim results from its combination dose escalation studies...
BeiGene and SpringWorks Therapeutics Report Positive Phase Ib Results for Lifirafenib and Mirdametinib Combination
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) and SpringWorks Therapeutics Inc., (NASDAQ: SWTX) have...
HanchorBio Receives FDA Approval for Multi-Region Clinical Study of HCB101 Fusion Protein
Taiwan-based HanchorBio has announced receiving the green light from the US FDA to conduct a...
HutchMed’s Elunate Receives NMPA Review for Second-Line Gastric Cancer Treatment
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that the National Medical Products Administration (NMPA)...
CBMG’s C-CAR031 Shows Promising Results in Phase I Study for Hepatocellular Carcinoma
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has published the results of the...
JS InnoPharm Initiates Phase Ib Study of AURKA Inhibitor VIC-1911 for EGFR-TKI Resistant NSCLC
JS InnoPharm Ltd, a Shanghai-based pharmaceutical company, announced that the first patient has been dosed...
Harbour Biomed to Present Early Clinical Data for CTLA-4 Antibody Combo at AACR 2023
China-based Harbour Biomed (HKG: 2142) is set to release early clinical data for its CTLA-4...
RemeGen’s Disitamab Vedotin (RC48) Clears for Phase I Study in HER2-Positive Tumors
RemeGen Ltd (HKG: 9995), a biopharmaceutical company, has announced that it has received approval from...